TARPLIN, DOWNS & YOUNG, LLC

Lobbying for AMYLYX PHARMACEUTICALS · Company dedicated to the development of potential therapies for neurodegenerative diseases

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $40,000.00 income · posted Oct 16, 2025

Lobbying activity 2

Medicare/Medicaid

rare disease and access to innovation

Health Issues

rare disease and access to innovation

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.